Buy Marksans Pharma; target of Rs 60: Centrum

We attended the AGM of  Marksans Pharma (MPL) and came out with a long-term positive outlook. We maintain Buy rating  with a TP of Rs60 based on 18x March’18E EPS of Rs3.4. MPL’s Q1FY17 results were impacted due to the decline in sales in the UK, Europe and RoW markets. We expect its performance to improve, as the US market is likely to report good growth led by recent approval of Metformin HCl ER tablets and Loratadine softgel capsules. MPL has filed ANDAs for 9 softgel capsules and expects approvals for the same. MPL is poised for good growth on TCL integration in the US and is likely to exhibit superior performance.For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.